Business UpdateApr 29, 2026, 07:06 AM
CCCC Advances Cemsidomide, Extends Cash Runway to 2028
AI Summary
C4 Therapeutics highlighted significant progress in its targeted protein degradation mission, advancing cemsidomide for multiple myeloma into Phase 2 and Phase 1b trials, including a collaboration with Pfizer. The company also implemented a new discovery strategy focused on inflammation, neuroinflammation, and neurodegeneration, and strengthened its balance sheet by raising $125 million, extending its cash runway to the end of 2028. The company also announced its 2026 Annual Meeting of Stockholders for June 24, 2026, to elect directors, approve executive compensation, ratify auditors, and amend its 2020 Stock Option and Incentive Plan.
Key Highlights
- Cemsidomide advanced into Phase 2 MOMENTUM trial for multiple myeloma.
- Initiated Phase 1b cemsidomide trial with Pfizer for multiple myeloma.
- New discovery strategy focused on inflammation, neuroinflammation, and neurodegeneration.
- Raised $125M in gross proceeds, extending cash runway to end of 2028.
- Anticipates potential cemsidomide NDA submission in 2028.
- Biogen advanced two C4T-designed candidates into Phase 1 clinical development.
- 2026 Annual Meeting of Stockholders scheduled for June 24, 2026.
- Shareholders to vote on election of three Class III directors.